AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Male Breast Cancer|Recurrent Breast Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Primary Peritoneal Cavity Cancer|Recurrent Renal Cell Cancer|Stage IV Breast Cancer|Stage IV Ovarian Epithelial Cancer|Stage IV Primary Peritoneal Cavity Cancer|Stage IV Renal Cell Cancer|Unspecified Adult Solid Tumor, Protocol Specific
Interventions: DRUG: AFP464|OTHER: pharmacological study|OTHER: laboratory biomarker analysis
Sponsor: National Cancer Institute (NCI)